Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An overview of binimetinib for the treatment of melanoma.

Expert opinion on pharmacotherapy - 1 May 2020

Specenier Pol

Abstract excerpt

INTRODUCTION: Approximately 50% of patients with metastatic melanoma have mutations in BRAF. Based on the results of prior phase III trials, the combination of a BRAF inhibitor (BRAFi) and a MEK inhibitor (MEKi) is the standard of care in patients with BRAF-mutant metastatic melanoma. AREAS COVERED: The author summarizes the available data on binimetinib, a reversible inhibitor of the kinase activity of MEK1 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Carbamates
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to MAP Kinase Kinase 1

Share to MAP Kinase Kinase 2

Share to Molecular Targeted Therapy

Share to Sulfonamides

Source

Identifiers

PMID: 32100585
DOI: 10.1080/14656566.2020.1729122

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An overview of binimetinib for the treatment of melanoma.PMID 32100585Read ↗

The discovery and development of binimetinib for the treatment of melanoma.Semantic proximity Read ↗

A review of binimetinib for the treatment of mutant cutaneous melanoma.Semantic proximity Read ↗

An evaluation of encorafenib for the treatment of melanoma.Semantic proximity Read ↗

Binimetinib for the treatment of NRAS-mutant melanoma.Semantic proximity Read ↗

STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma.Semantic proximity Read ↗

Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.Semantic proximity Read ↗

Preclinical discovery and clinical development of encorafenib for the treatment of melanoma.Semantic proximity Read ↗

Development of encorafenib for BRAF-mutated advanced melanoma.Semantic proximity Read ↗

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.Semantic proximity Read ↗

First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study.Semantic proximity Read ↗

Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?Semantic proximity Read ↗

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.